Athenex Inc ATNX

NAS: ATNX | ISIN: US04685N1037   26/07/2023
0,006 USD (+103,33%)
(+103,33%)   26/07/2023

1 mei 2023 · Quantum Leap Healthcare Collaborative Announces Result of Oral Paclitaxel in Combination with a PD-1 and Carboplatin from I-SPY2 TRIAL at ASCO · Persbericht

3 mei 2021 · MAY 3, 2021 ATNX INVESTOR DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Athenex, Inc. · Persbericht

18 maart 2021 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Athenex, Inc. - ATNX · Persbericht

18 maart 2021 · ATNX INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Athenex, Inc. · Persbericht

18 maart 2021 · ATNX BREAKING NEWS: ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Athenex, Inc. Investors to Secure Counsel Before Important Deadline - ATNX · Persbericht

17 maart 2021 · Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Athenex, Inc. (ATNX) · Persbericht

12 maart 2021 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Athenex, Inc. - ATNX · Persbericht

9 maart 2021 · HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Athenex (ATNX) Investors with Losses to Contact Its Attorneys, Securities Fraud Case Filed · Persbericht

6 maart 2021 · ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Athenex, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline - ATNX · Persbericht

5 maart 2021 · INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athenex, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm · Persbericht

5 maart 2021 · Bronstein, Gewirtz & Grossman, LLC Notifies Athenex, Inc. (ATNX) Investors of Class Action and Encourages Shareholders to Contact the Firm · Persbericht

5 maart 2021 · ATNX INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Athenex, Inc. · Persbericht

4 maart 2021 · ATNX LOSSES ALERT: Bernstein Liebhard LLP is Investigating Athenex, Inc. For Violations of the Securities Laws · Persbericht

3 maart 2021 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Athenex, Inc. - ATNX · Persbericht

3 maart 2021 · HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Athenex (ATNX) Investors with Losses to Contact Its Attorneys, ATNX Reports FDA Complete Response Letter · Persbericht

1 maart 2021 · Athenex Provides Fourth Quarter and Full Year 2020 Corporate and Financial Update · Persbericht

18 februari 2021 · Almirall U.S. Launches Klisyri® (tirbanibulin), a New, Innovative Topical Treatment for Actinic Keratosis · Persbericht

11 februari 2021 · Almirall announces New England Journal of Medicine publication of Phase III data demonstrating efficacy and safety of Klisyri® (tirbanibulin) · Persbericht

25 januari 2021 · CEO Dr. Johnson Lau Recuperating from COVID at Home · Persbericht

8 januari 2021 · CEO Dr. Johnson Lau Contracts COVID-19 · Persbericht

Mijn selecties